Appus
Autoimmune Disease
Key Facts
About BioVectis
BioVectis operates as a hybrid company, combining a tools-and-platform business with internal therapeutic/diagnostic R&D. Its flagship DNA Pointer System offers unparalleled temperature-controlled native electrophoresis, serving as a critical research tool for academia and pharma in studying molecular interactions and genetic heterogeneity. Alongside this platform, BioVectis is developing several proprietary programs, including an autoimmune disease therapy (Appus), a recombinant poultry vaccine (Scutum N), and diagnostic platforms for volatile organic compounds (VOC) and biological age estimation. The company appears to be a privately-held, revenue-generating entity leveraging its proprietary technology for both product sales and collaborative research.
View full company profileTherapeutic Areas
Other Autoimmune Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Fusion Immunotherapeutic | HCW Biologics | Clinical Trial |
| Autoimmune Disease Program | Carisma Therapeutics | Discovery |
| Not Specified (Autoimmune Focus) | Narwhal Bio | Pre-clinical |
| Undisclosed Precision Biologic | Rhapsogen | Pre-clinical |
| First-in-class autoimmune disorder target | Genesis Therapeutics | Pre-clinical |
| GIM-407 | Georgiamune | Preclinical |
| Autoimmunity Program | Accipiter Biosciences | Preclinical |
| Undisclosed Autoimmune Program | TianTi Biotherapeutics | Preclinical |
| Undisclosed Transcription Factor | Talus Bioscience | Discovery |
| Leap 1121 | Ability Biotherapeutics | Preclinical |
| ALLO-329 | Allogene Therapeutics | Phase 1 |